Lille, France

Salomon Manier

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Boston, MA (US) (2018)
  • Lille, FR (2021)

Company Filing History:


Years Active: 2018-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Salomon Manier: Innovator in Hematological Research

Introduction

Salomon Manier is a notable inventor based in Lille, France, recognized for his contributions to the field of hematological malignancies. With a focus on non-invasive diagnostic methods, he has made significant strides in understanding plasma cell dyscrasias. His work has led to the development of innovative techniques that enhance patient care and treatment outcomes.

Latest Patents

Salomon Manier holds 2 patents that reflect his expertise in the diagnosis and treatment of hematological conditions. His latest patents include methods for identifying genetic abnormalities in plasma cell dyscrasias. These methods provide non-invasive approaches to monitor disease progression and treatment efficacy, offering advantages over traditional invasive biopsies. Additionally, he has developed compositions and methods for diagnosing and treating hematological malignancies based on the differential expression of microRNAs in blood samples. This innovation allows for better staging of the disease and assessment of treatment effectiveness.

Career Highlights

Manier is affiliated with the Dana-Farber Cancer Institute Inc., where he collaborates with leading researchers in the field. His work has been instrumental in advancing the understanding of hematological malignancies and improving diagnostic techniques.

Collaborations

Some of his notable coworkers include Irene M. Ghobrial and Aldo M. Roccaro, who share his commitment to advancing cancer research and treatment.

Conclusion

Salomon Manier's innovative contributions to hematological research have paved the way for improved diagnostic and treatment methods. His work continues to impact the field significantly, enhancing patient outcomes in hematological malignancies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…